Study to Assess the Efficacy, Safety, and Tolerability of AZD8529 in Adult Schizophrenia Patients

Completed · Phase 2 · Has a placebo group

Conditions studied: Schizophrenia

In brief

The purpose of this study is to determine whether treatment with daily oral dose of AZD8529 40 mg administered over 28 days is safe, well tolerated and improves main symptoms of schizophrenia in adult schizophrenia patients.

Key facts

Study ID

NCT00921804

Run by

AstraZeneca

People needed

296

Starts

2009-06-01

Expected to finish

2010-05-01

Last updated by the study team

2010-06-30

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient will need to read, understand and sign an informed consent prior to any study specific procedures
• Patient will have certain schizophrenia symptoms deemed by the investigator as appropriate for the study entry

You may not qualify if…

• Patients will be excluded based on recent history of significant illness or current disease as assessed by the investigator during screening process (based on physical examination, laboratory studies and electrocardiogram studies)
• Patients will be excluded if urine drug screen test show positive results
• Smoking of more than 2 packs of cigarettes a day

Where it is running

• Research Site — Garden Grove, California, United States
• Research Site — Glendale, California, United States
• Research Site — Rockville, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.